A comprehensive multiplex real-time PCR assay designed for rapid detection of clinically significant bloodstream pathogens and major antimicrobial resistance (AMR) genes directly from Whole Blood (EDTA). 44 targets in a single run — enabling targeted antimicrobial stewardship and rapid sepsis management decisions.
Sepsis is a medical emergency requiring rapid diagnostic intervention. Traditional blood culture methods take 24–72 hours to identify causative pathogens and resistance profiles, risking patient outcomes while empiric broad-spectrum antibiotics are administered.
The Genplex™ Blood Sepsis Panel with AMR delivers molecular identification of 44 key targets in hours, helping clinicians implement targeted, evidence-based antimicrobial therapy quickly — directly supporting antimicrobial stewardship programs.
The panel covers Gram-positive bacteria (12 targets), Gram-negative bacteria (15 targets), Yeast/Fungi (6 targets), and 11 AMR resistance genes including mecA, mecC, vanA, vanB, blaKPC, blaNDM, blaOXA-48, and more — all from a single Whole Blood (EDTA) specimen.
Advanced molecular diagnostic capabilities engineered for clinical excellence and research-grade precision.
Delivers bloodstream pathogen identification in hours, not days — optimizing time-to-treatment in critical sepsis conditions.
Accurate identification directly from clinical specimen templates, reducing false positives and culture contamination concerns.
Simultaneously targets 44 clinically significant pathogens and resistance profiles in one reaction.
11 AMR markers enable targeted antibiotic therapy selection and minimize empiric broad-spectrum antibiotic use.
Built-in internal amplification/extraction control ensures result validity in every run.
Gram-positives, Gram-negatives, Candida/Yeast, and AMR resistance genes all in one assay.
Comprehensive multiplex detection covering a broad spectrum of clinically relevant pathogens and resistance markers.
Designed for diverse diagnostic and research use cases across the clinical spectrum.
Rapid identification of bloodstream pathogens in septic patients for early targeted antimicrobial therapy.
Comprehensive profiling of pathogens and AMR status in critically ill patients for improved outcomes.
Use AMR gene detection to guide antibiotic selection and reduce unnecessary broad-spectrum antibiotic use.
Screen post-operative patients for bloodstream infections and resistant organisms.
| Parameter | Value / Description |
|---|---|
| Sample Type | Whole Blood (EDTA) |
| Total Targets | 44 (Gram+, Gram−, Yeast, AMR) |
| Gram-Positive | 12 bacterial targets |
| Gram-Negative | 15 bacterial targets |
| Yeast/Fungi | 6 targets |
| AMR Resistance Genes | 11 targets (mecA, mecC, vanA, vanB, blaKPC, blaNDM, blaOXA-48, blaIMP, blaVIM, blaCTX-M, ESBL) |
| Internal Control | Included |
| Intended Use | In Vitro Diagnostic (IVD) |
| Storage | -20°C |
For in vitro diagnostic use. Contact your regional distributor or ProbGen representative to place an order.
| Product Name | Cat. No. | Pack Size |
|---|---|---|
| Genplex™ Blood Sepsis Panel with AMR | GP1092 | 48 tests |
| Genplex™ Blood Sepsis Panel with AMR | GP1093 | 96 tests |
Contact our scientific team for technical specifications, bulk pricing, or to request a demonstration of our diagnostics solutions.
Contact Us All Products